ANALYSIS OF SERUM SOLUBLE INTERFERON α/β RECEPTOR LEVELS IN PATIENTS WITH UROLOGICAL DISEASES
-
- Kanayama Hiro-omi
- Department of Urology, University of Tokushima School of Medicine
-
- Takahashi Masayuki
- Department of Urology, University of Tokushima School of Medicine
-
- Nishitani Masaaki
- Department of Urology, University of Tokushima School of Medicine
-
- Kagawa Susumu
- Department of Urology, University of Tokushima School of Medicine
Bibliographic Information
- Other Title
-
- 泌尿器科疾患における血清中可溶性インターフェロンα/βレセプターの意義
- ANALYSIS OF SERUM SOLUBLE INTERFERON ^|^alpha;/^|^beta; RECEPTOR LEVELS IN PATIENTS WITH UROLOGICAL DISEASES
Search this article
Description
(Purpose) In order to define the clinical significance of serum soluble Interferon α/β receptor (sIFN α/βR) levels, we determined sIFN α/βR concentrations in serum of patients with urological benign and malignant diseases.<br>(Materials and Methods) Serum sIFN α/βR levels were measured in normal control (n=2), patients with benign diseases (n=50) included urolithiasis (n=16), prostatic hypertrophy (n=13), and malignant diseases included bladder cancer (n=49), renal cell carcinoma (n=30) and prostate cancer (n=36) by the enzyme linked immunosolbent assay (ELISA) using monoclonal and polyclonal antibodies. The levels of serum sIFN α/βR was correlated with the results of other hematoserological examinations, and clinical or pathological characters of each urological malignancies.<br>(Results) The serum sIFN α/βR levels (pg/ml) of patients with urolithiasis (2, 370.6±640.6, p=0.0002), benign prostatic hypertrophy (2, 121.1±550.6, p=0.0103), bladder cancer (2, 512.3±1, 012.3, p=0.0006), renal cell carcinoma (2, 686.4±1, 510.9, p=0.0046), prostate cancer (3, 188.7±1, 788., p=0.0003) showed significantly higher values than those of controls (1, 709.5±346.7). Moreover, we found statistically significant correlations among serum creatinine (Cr) levels and sIFN α/βR levels. However, there were no correlations between the sIFN α/βR levels and clinical stage, or histological grade in the patients with bladder cancer or prostate cancer, whenever the levels of sIFN α/βR were corrected by serum Cr levels. On the other hand, high level of corrected serum sIFN α/βR was observed in patients with high stage or high grade renal cell carcinoma, but not significant statistically.<br>(Conclusions) Elevated serum sIFN α/βR was observed in patients with urological disease. Further examinations should be necessary to determine the clinical usefulness of serum sIFN α/βR.
Journal
-
- The Japanese Journal of Urology
-
The Japanese Journal of Urology 91 (9), 630-636, 2000
THE JAPANESE UROLOGICAL ASSOCIATION
- Tweet
Details 詳細情報について
-
- CRID
- 1390001205057788288
-
- NII Article ID
- 110003060624
-
- NII Book ID
- AN00196577
-
- ISSN
- 18847110
- 00215287
-
- PubMed
- 11068427
-
- Data Source
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed